Sales Performance - Global Q1 sales reached AUD$2.0 million, representing a 34% increase compared to the prior comparative period (pcp) [1] - Australia Q1 sales were AUD$1.6 million, up 52% on pcp [1] - USA Q1 sales increased to AUD$0.4 million, reflecting a 44% growth on pcp [1] - Canada Q1 sales were AUD$0.0 million, down 92% on pcp [1] Growth Drivers - Continued growth in Australia attributed to increased awareness from digital and social media marketing, same store growth, new store openings, and increased travel from South East Asia [3] - In the U.S., sales growth driven by marketing initiatives including improved online presence on Amazon, local social media pages, and increased paid and organic social media marketing [4] - In Canada, sales are expected to improve as consumer promotions are anticipated towards the end of the calendar year, with efforts to build brand awareness through educational programs and promotions [5] Product Information - Travelan® is an over-the-counter immune supplement designed to reduce the likelihood of travelers' diarrhea caused by pathogenic bacteria [7] - The product is available in Australia as a listed medicine, in Canada as a licensed natural health product, and in the U.S. as a dietary supplement [8]

Company Overview - Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases [5] - The company is listed on both the ASX (ASX: IMC) and NASDAQ (NASDAQ: IMRN) [5] Recent Developments - Immuron has entered into a partnership with InvestorHub to enhance direct engagement with investors through an interactive investor hub [1][2] - The investor hub will serve as a platform for content and communication, including videos, educational materials, interviews, and corporate research [2] Upcoming Milestones - CEO Steven Lydeamore highlighted the importance of improving communication with shareholders, especially with several near-term milestones approaching [3] - Immuron anticipates the submission and approval of the FDA for the IMM-529 Investigational New Drug (IND) and the release of topline results for the Travelan® (IMM-124E) clinical trial by the end of the calendar year [3] Product Information - Travelan® is an orally administered passive immunotherapy designed to reduce the likelihood of travelers' diarrhea, which is caused by pathogenic bacteria [6] - The product is available in Australia as a listed medicine and is sold as a dietary supplement in the U.S. for digestive tract protection [6] Technology Platform - Immuron's proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum, allowing for the development of medicines targeting a wide range of infectious diseases [9] - The platform can effectively block viruses or bacteria at mucosal surfaces and neutralize toxins produced by these pathogens [9] Clinical Development - IMM-529 is being developed as an adjunctive therapy for the prevention and treatment of recurrent Clostridioides difficile infection (CDI) [12] - The product targets multiple components of C. diff virulence, showing promising results in pre-clinical models for preventing primary disease and protecting against disease recurrence [14][15] Market Insights - The IBS treatment market in Australia is part of the broader "Digestives & Intestinal Remedies" market, projected to generate approximately AU$221.14 million in 2025, with an annual growth rate of 3.28% [18]